SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miles Rhyne Hoffman, CFA who wrote (179)1/20/1997 12:23:00 AM
From: Larry Liebman   of 6136
 
It's titled,"With AIDS Advance, More Disappointment", leading one to speculate that this is a negative article regarding protease inhibitors...This would be an error..In fact, the discussion is largely about the experience of MD's of a decreasing mortality of AIDS patients...An example is cited at Case Western where an average of 8 of 650 AIDS patients died each month over 3 years..In December, for the first time, there were none...The Abelson article was of a similar ilk, pointing out that many AIDS patients do not respond and/or cannot tolerate the side effects...However, a significant number of people do respond to treatment...The questions of long term outcome, "cure", the right way to dose, will continue to be studied and argued...What people would be doing if there were no protease inhibitors available?.....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News